Scarica l'app Stockscreener
0.3002
0.40%
0.0012
Dopo l'orario di chiusura:
.30
-0.0002
-0.07%
Precedente Chiudi:
$0.299
Aprire:
$0.316
Volume 24 ore:
115.62K
Relative Volume:
0.47
Capitalizzazione di mercato:
$9.35M
Reddito:
$38,000
Utile/perdita netta:
$-51.55M
Rapporto P/E:
-0.1563
EPS:
-1.9207
Flusso di cassa netto:
$-37.07M
1 W Prestazione:
-11.99%
1M Prestazione:
-13.98%
6M Prestazione:
-69.78%
1 anno Prestazione:
-76.91%
Intervallo 1D:
$0.293
$0.316
Intervallo di 1 settimana:
$0.29
$0.36
Portata 52W:
$0.29
$2.88
Senti Biosciences Holdings Inc Stock (SNTI) Company Profile
Nome
Senti Biosciences Holdings Inc
Settore
Industria
Telefono
(650) 239-2030
Indirizzo
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.3002 | 9.31M | 38,000 | -51.55M | -37.07M | -1.9207 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Senti Biosciences Holdings Inc Stock (SNTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-06 | Iniziato | Laidlaw | Buy |
| 2022-10-07 | Iniziato | Morgan Stanley | Equal-Weight |
Senti Biosciences Holdings Inc Borsa (SNTI) Ultime notizie
Convertible notes could hand one investor control of Senti (NASDAQ: SNTI) - Stock Titan
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - stockstotrade.com
Senti Biosciences Holds Near $0.34 as SNTI Tests Key Support ZoneStrong Buy Stocks - dars.gov.et
Senti Biosciences Secures Equity Commitment Amid Merger Plans - TipRanks
Senti Biosciences Adds $2 Million Convertible Debt, $2.5 Million Equity Commitment Ahead of Merger - TradingView
Senti Biosciences Inc (NASDAQ: SNTI) Share Price, SNTI Stock News, SNTI Share Price & Updates - Kalkine
Senti Biosciences amends securities agreement, adds note tranche - TipRanks
Senti Biosciences Holdings Received Notice of Noncompliance - TradingView
SNTI Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Senti Biosciences (SNTI) Gains 2.35% as Shares Hold Above Key Support at $0.36Risk Reward Setups - vinanet.vn
Senti Biosciences (NASDAQ:SNTI) to spin off SENTI-202 pipeline to Celadon-backed NewCo via CVRs - Kalkine
SNTI|Senti Biosciences Inc|Price:0.373|Chg%:-0.030 - TradingKey
$Senti Biosciences (SNTI.US)$ - Moomoo
Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Senti Biosciences (SNTI) Hovers Near Support as Stock Consolidates Below $0.45ETF Outflow Streak - vinanet.vn
Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com - Investing.com South Africa
Senti Biosciences (SNTI) backer plans merger and $6M funding - Stock Titan
Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform - Quiver Quantitative
Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs - TradingView
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Te - Yahoo Finance
SNTI Should I Buy - Intellectia AI
Price to sales forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Price to book forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBITDA forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI) - TradingView
SNTI Forecast — Price Target — Prediction for 2027 - TradingView
SNTI Q1 2026 Earnings: Narrower Loss Surprises Amid Pre-Revenue StageGuidance Accuracy Score - dars.gov.et
Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes - Stock Titan
Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SNTI Q1 2026 Earnings: Modest EPS Beat Amid Development ProgressEarnings Call Transcript - dars.gov.et
Senti Biosciences Inc (SNTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction - Business Wire
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
SNTISenti Biosciences Holdings Inc Options - Finviz
Senti Biosciences Inc. (SNTI) Stays Near Key Support Following Modest UptickTake Profit Levels - The Legal Advocate
Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR - Stock Titan
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch - Bez Kabli
Senti Biosciences Inc. Q1 2026 Earnings: Narrowing Losses and Gene Circuitry ProgressCFO Commentary Report - Newser
Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy - The Clinical Trial Vanguard
Senti Biosciences Holdings, Inc.Common Stock (NQ: SNTI - The Chronicle-Journal
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - TipRanks
SNTI Maintained by Chardan Capital -- Price Target Raised to $12 - GuruFocus
Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating - Moomoo
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Sahm
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
Senti Biosciences Holdings Inc Azioni (SNTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):